Clobetasol Propionate
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Clobetasol Propionate
- Clobetasol Propionate: From Topical Corticosteroid Use to Vulvar Inverted Follicular Keratosis
Clobetasol Propionate: From Topical Corticosteroid Use to Vulvar Inverted Follicular Keratosis
One-Sentence Summary
Clobetasol propionate is a high-potency topical corticosteroid marketed in the US in several dosage forms, but the source data list no approved indication text for it. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis. No clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Clobetasol is a high-potency glucocorticoid receptor agonist with anti-inflammatory and antiproliferative effects. This is general pharmacology, not something the source data confirm.
The link to a benign follicular keratotic lesion is speculative. This lesion is usually managed by excision or biopsy, and no source data connect clobetasol to it. The high TxGNN score is a computational prediction only, and it has no clinical support at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The record lists 20 authorizations in total. The main ones are below; none includes approved indication text in the source data.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA211494 | Clobetasol Propionate | Solution | A-S Medication Solutions |
| ANDA210034 | Clobetasol Propionate | Cream | Bryant Ranch Prepack |
| ANDA212982 | Clobetasol Propionate Cream USP, 0.05% | Cream | Encube Ethicals, Inc. |
| ANDA205249 | Clobetasol Propionate | Lotion | Viona Pharmaceuticals Inc |
| ANDA090974 | Clobetasol Propionate | Shampoo | Bryant Ranch Prepack |
Other marketed forms across the 20 authorizations include ointment and gel.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no trials, no literature, and only a speculative mechanistic link. Evidence is at L5 (model prediction only).
To proceed, the following is needed:
- Package insert warnings, contraindications and approved indications
- Mechanism of action data (for example from DrugBank)
- Any clinical or case-level evidence for clobetasol in this specific lesion
- Comparison with other predicted indications for this drug that have more support. Acne keloidalis (open-label study, L3) and exanthem (indirect trial evidence in steroid-responsive dermatoses, L3) are the two examples in this pack. Both are still research questions and neither is a confirmed new use.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.